Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

NCT03864419 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Closed per SRC Low Accrual Policy

Conditions

Burkitt Lymphoma
KSHV-associated Multicentric Castleman Disease
Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL: Rituximab and Hyaluronidase Human
DRUG: Cyclophosphamide
DRUG: Vincristine
DRUG: Methotrexate
DRUG: Doxorubicin
DRUG: Doxorubicin Hydrochloride
DRUG: Prednisone
DRUG: Etoposide
BIOLOGICAL: Rituximab

Sponsor

Fred Hutchinson Cancer Center